New Neurovascular Firm Gets Private Equity Backing

Nfocus Neuromedical, a Menlo Park, CA, designer of aneurysm and fistula treatment devices, announced on Tuesday a $20.3 million Series B private equity financing. Nfocus is a newly created company that resulted from a merger, also announced on Tuesday, between CardioVasc and Acta Vascular Systems. “The acquisition of Acta Vascular will provide Nfocus with a broader presence and an immediate impact in the area of neurovascular diseases and hemorrhagic stroke,” said CardioVasc’s founder, Mir Imran. A self-proclaimed “serial medical device entrepreneur,” Imran also is the founder of InCube Laboratories, a medical device incubator that develops companies.

Nfocus will specialize in endovascular treatment devices that provide “faster, simpler and more permanent treatment of hemorrhagic stroke,” according to a company statement. Such devices provide interventional neuroradiologists and neurosurgeons with additional options when treating patients who may have inoperable conditions.

The Series B financing came from Boston-based Oxford Bioscience Partners and Palo Alto, CA-based Technology Partners, together with existing investor ePlanet Ventures. The funds will enable Nfocus to immediately begin marketing its aneurysm and fistula treatment devices in the U.S. and Europe.

The comments are closed.